viewMountain Valley MD Holdings Inc

Mountain Valley MD gets approval for COVID-19 clearance trial in Level 4 Bio Hazard Facility

Mountain Valley MD (CSE: MVMD) CEO Dennis Hancock and Director of Life Sciences Mike Farber joined Steve Darling with news the company will be conducting a Bio-Safety Level 4 lab study of COVID-19 viral clearance to prove out the Company’s solubilized Ivermectin technology versus commercially available oral form in the time and efficacy in viral clearance.

Farber telling Proactive what that means while Hancock talks about the timing of the study and how excited they are to be doing this one of the kind study.

Quick facts: Mountain Valley MD Holdings Inc

Price: 1.35 CAD

Market: CSE
Market Cap: $378.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...


Mountain Valley MD proceeding with program to get FDA approval for Novel...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock joined Steve Darling with Proactive to bring news the company has engaged the services of Camargo Pharmaceutical services to help navigate the waters of the FDA as they continue with their application for Novel Ivectosol. Hancock...

3 days, 18 hours ago

2 min read